Sirtuin 6 nuclear localization at cortical brain level of young diabetic mice: An immunohistochemical study

Acta Histochemica

Volumn 116, Issue 1, 2014, Pages 272-277

  Favero, Gaia ^a   Rezzani, Rita ^a   Rodella, Luigi Fabrizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Brain cortex; Immunohistochemistry; Mice; Sirtuin 6; Type II Diabetes mellitus

Indexed keywords

SIRT6 PROTEIN, MOUSE; SIRTUIN;

ACTIVE TRANSPORT; ANIMAL; BRAIN CORTEX; CELL NUCLEUS; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; CEREBRAL CORTEX; DIABETES MELLITUS, TYPE 2; IMMUNOHISTOCHEMISTRY; MALE; MICE, OBESE; SIRTUINS;

EID: 84894905267     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.08.006     Document Type: Article

References (40)

1. Accardi G., Caruso C., Colonna-Romano G., Camarda C., Monastero R., Candore G. Can Alzheimer disease be a form of type 3 diabetes. Rejuvenation Res 2012, 5:217-221.
2. Acee A.M. Type 2 diabetes and vascular dementia: assessment and clinical strategies of care. Medsurg Nurs 2012, 21:349-353. 384.
3. Akter K., Lanza E.A., Martin S.A., Myronyuk N., Rua M., Raffa R.B. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment. Br J Clin Pharmacol 2011, 71:365-376.
4. Alberti K.G., Zimmet P., Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
5. Baur J.A., Ungvari Z., Minor R.K., Le Couteur D.G., de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan. Nat Rev Drug Discov 2012, 11:443-461.
6. Beauharnois J.M., Bolívar B.E., Welch J.T. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol Biosyst 2013, 9:1789-1806.
7. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4:47-52.
8. Dominy J.E, Lee Y., Jedrychowski M.P., Chim H., Jurczak M.J., Camporez J.P., et al. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell 2012, 48:900-913.
9. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press.
10. Gahete M.D., Córdoba-Chacón J., Kineman R.D., Luque R.M., Castaño J.P. Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease. Peptides 2011, 32:2225-2228.
11. Haigis M.C., Guarente L.P. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006, 20:2913-2921.
12. Jia G., Su L., Singhal S., Liu X. Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem 2012, 364:345-350.
13. Jin J., Albertz J., Guo Z., Peng Q., Rudow G., Troncoso J.C., et al. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem 2013, 125:410-419.
14. Kaiyala K.J., Prigeon R.L., Kahn S.E., Woods S.C., Schwartz M.W. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000, 49:1525-1533.
15. Kanfi Y., Peshti V., Gil R., Naiman S., Nahum L., Levin E., et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010, 9:162-173.
16. Kanfi Y., Shalman R., Peshti V., Pilosof S.N., Gozlan Y.M., Pearson K.J., et al. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett 2008, 582:543-548.
17. Kitada M., Kume S., Takeda-Watanabe A., Kanasaki K., Koya D. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013, 124:153-164.
18. Lam J.L., Jiang Y., Zhang T., Zhang E.Y., Smith B.J. Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice. Drug Metab Dispos 2010, 38:2252-2258.
19. Lee O.H., Kim J., Kim J.M., Lee H., Kim E.H., Bae S.K., Choi Y., Nam H.S., Heo J.H. Decreased expression of sirtuin 6 is associated with release of high mobility group box-1 after cerebral ischemia. Biochem Biophys Res Commun 2013, [Epub ahead of print].
20. Liszt G., Ford E., Kurtev M., Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005, 280:21313-21320.
21. Marrazzo G., Bosco P., La Delia F., Scapagnini G., Di Giacomo C., Malaguarnera M., et al. Neuroprotective effect of silibinin in diabetic mice. Neurosci Lett 2011, 504:252-256.
22. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005, 16:4623-4635.
23. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
24. Nerurkar P.V., Johns L.M., Buesa L.M., Kipyakwai G., Volper E., Sato R., et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation 2011, 8:64.
25. Outeiro T.F., Marques O., Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008, 1782:363-369.
26. Panza F., Frisardi V., Capurso C., Imbimbo B.P., Vendemiale G., Santamato A., et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 2010, 21:691-724.
27. Park C.H., Tanaka T., Yokozawa T. Anti-diabetic action of 7-O-galloyl-d-sedoheptulose, a polyphenol from Corni fructus, through ameliorating inflammation and inflammation-related oxidative stress in the pancreas of type 2 diabetics. Biol Pharm Bull 2013, 36:723-732.
28. Polyakova O., Borman S., Grimley R., Vamathevan J., Hayes B., Solari R. Identification of novel interacting partners of Sirtuin6. PLoS ONE 2012, 7:e51555.
29. Reijmer Y.D., van den Berg E., Ruis C., Kappelle L.J., Biessels G.J. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010, 26:507-519.
30. Roberts C.K., Hevener A.L., Barnard R.J. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Comp Physiol 2013, 3:1-58.
31. Rubio-Ruiz M.E., El Hafidi M., Perez-Torres I., Baños G., Guarner V. Medicinal agents and metabolic syndrome. Curr Med Chem 2013, 20:2626-2640.
32. Schwer B., Schumacher B., Lombard D.B., Xiao C., Kurtev M.V., Gao J., et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci USA 2010, 107:21790-21794.
33. Sebastián C., Satterstrom F.K., Haigis M.C., Mostoslavsky R. From sirtuin biology to human diseases: an update. J Biol Chem 2012, 287:42444-42452.
34. Simkova A., Bulas J., Balogova S., Reptova A., Kisa B., Luha J., et al. Metabolic syndrome and its effect on aortic stiffness in premenopausal women. Bratisl Lek Listy 2013, 114:279-282.
35. Solfrizzi V., Scafato E., Capurso C., D'Introno A., Colacicco A.M., Frisardi V., et al. Italian Longitudinal Study on Aging Working Group. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol Aging 2011, 32:1932-1941.
36. Umegaki H. Neurocognitive dysfunction in old diabetes: management and treatment. Adv Exp Med Biol 2012, 771:465-470.
37. Wang H.F., Li Q., Feng R.L., Wen T.Q. Transcription levels of sirtuin family in neural stem cells and brain tissues of adult mice. Cell Mol Biol (Noisy-le-grand) 2012, 58(Suppl.):OL1737-OL1743.
38. Webster K.A. A sirtuin link between metabolism and heart disease. Nat Med 2012, 18:1617-1619.
39. Zhong L., D'Urso A., Toiber D., Sebastian C., Henry R.E., Vadysirisack D.D. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140:280-293.
40. Zhong L., Mostoslavsky R. SIRT6: a master epigenetic gatekeeper of glucose metabolism. Transcription 2010, 1:17-21.